Boosted protease inhibitor monotherapy in HIV-infected adults: Outputs from a pan-European expert panel meeting

AIDS Research and Therapy

Volumn 10, Issue 1, 2013, Pages

  Arribas, José R ^a   Doroana, Manuela ^b   Turner, Dan ^c   Vandekerckhove, Linos ^d   Streinu Cercel, Adrian ^e  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e HIV/AIDS Academy   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL THERAPY; ATROPHY; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG UTILIZATION; EUROPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INSULIN RESISTANCE; LIPODYSTROPHY; MONOTHERAPY; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

EID: 84872687219     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-10-3     Document Type: Review

References (36)

1. Mocroft A, Phillips AN, Soriano V. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005, 21:527-536.
2. European AIDS Clinical Society (EACS) guidelines. Version 6.1. November 2011. [http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41].
3. DHHS Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (14 October 2010). [http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf].
4. Aggiornate le linee guida sull'utilizzo degli antiretrovirali nelle persone con infezione HIV-1 (18 luglio 2012). [http://www.salute.gov.it/hiv/newsHiv.jsp?id=2106&menu=inevidenza&lingua=italiano].
5. Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2012). [http://www.gesida-seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2012-Documentoconsenso-TAR-adulto-verordenador.pdf].
6. Mathis S, Khanlari B, Pulido F. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One 2011, 6:e22003.
7. Valantin M, Duvivier C, Lambert C. Long-Term Efficacy of Darunavir/ritonavir Monotherapy in patients with HIV-1 viral suppression in the MONOI-ANRS 136 study: Results at 96 Weeks. CROI 2011. Abstract P534.
8. Katlama C, Valantin MA, Algarte-Genin M. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized, open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010, 24:2365-2374.
9. Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. Antivir Ther 2011, 16:59-65.
10. Arribas JR, Pulido F, Delgado R. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005, 40:280-287.
11. Pulido F, Pérez-Valero I, Delgado R. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009, 14:195-201.
12. Campo RE, Da Silva BA, Cotte L. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. AIDS Res Hum Retroviruses 2009, 25:269-275.
13. Lambert-Niclot S, Flandre P, Valantin MA. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis 2011, 204:1211-1216.
14. Nunes EP, Santini de Oliveira M, Merçon M. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials 2009, 10:368-374.
15. Marcelin AG, Lambert-Niclot S, Peytavin G. Baseline HIV RNA ultrasensitive assay and viral DNA predict rise in plasma viral load in patients of MONOI-ANRS 136 trial (DRV/r monotherapy vs 2 NRTI + DRV/r). CROI 2011. Poster 533.
16. Gutmann C, Cusini A, Günthard HF. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010, 24:2347-2354.
17. Arribas JR, Montes ML, Prakash M. The MONET trial: correlation between hepatitis C co-infection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline. ISHEID 2010. Abstract O-15.
18. Bisson G, Gross R, Miller V. Monitoring of long-term toxicities of HIV treatments: an international perspective. AIDS 2003, 17:2407-2417.
19. DAD Study Group Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735. DAD Study Group.
20. Arribas JR, Clumeck N, Nelson M. The MONET trial: Week 144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r + 2 NRTIs, for patients with HIV RNA <50 copies/mL at baseline. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 2011. Abstract MOPE216.
21. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009, 23:279-291.
22. Letendre S, Marquie-Beck J, Capparelli E. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65:65-70.
23. Letendre S, FitzSimons C, Ellis R. Correlates of CSF viral loads in 1221 volunteers of the CHARTER cohort. CROI 2010. Abstract 172.
24. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004, 157:3-10.
25. Arribas J, Hill A. Neurocognitive disorders during antiretroviral treatment, despite full HIV RNA suppression. HIV Ther 2010, 4:257-260.
26. Schweinsburg BC, Taylor MJ, Alhassoon OM. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 2005, 11:356-364.
27. Perez-Valero I, Bayon C, Cambron I, Gonzales A, Arribas JR. Protease inhibitor monotherapy and the CNS: peace of mind?. J Antimicrob Chemother 2011, 66:1954-1962.
28. Lambert-Niclot S, Peytavin G, Duvivier C. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother 2010, 54:4910-4913.
29. Yeh RF, Hammill HA, Fiscus SA. Single Agent Therapy (SAT) with lopinavir/ritonavir (LPV/r) controls HIV-1 viral replication in the female genital tract. EACS 2007. Abstract P7.7/02.
30. Martin A, Smith DE, Carr A. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004, 18:1029-1036.
31. Cameron DW, da Silva BA, Arribas JR. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008, 198:234-240.
32. Valantin M, Flandre P, Kolta S. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTI + DRV/r in the MONOI-ANRS 136 randomized trial: results at 48 Weeks. CROI 2010. Abstract 721.
33. Guaraldi G, Zona S, Cossarizza A. Impact of switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in virologically suppressed HIV-infected adults. The MONARCH randomized trial. EACS 2011. Poster PE7.5/4.
34. Rieger A, Banhegyi D, Schmidt W. The MONET trial 96 week analysis: darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA < 50 copies/mL at baseline. IAC 2010. Abstract THLBB209.
35. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011, 57:773-780.
36. Winston A, Arribas JR, Hill A. Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir (DRV/r) with or without nucleoside analogues (NRTIs). Antivir Ther 2011, 16(Suppl 2):A65. Abstract P50.